3 assets in Plasmacytoid Variant Infiltrating Bladder Urothelial Carcinoma

Therapeutic assets addressing Plasmacytoid Variant Infiltrating Bladder Urothelial Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Plasmacytoid Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Nivolumab Plasmacytoid Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Ipilimumab Plasmacytoid Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	B (59)